RESUMO
Two hundred and eighty-four patients with acute conjunctivitis were enrolled in a double-masked study comparing norfloxacin ophthalmic solution with placebo. The proportion of patients who were clinically improved after 5 days treatment was 88.1% in the norfloxacin group and 71.6% in the placebo group (p less than 0.01). The proportion of patients who had all organisms eradicated, including the coagulase-negative staphylococci, after two to three days treatment was 52.7% for norfloxacin and 23.9% for placebo (p less than 0.01) and 64.7% and 26.3% (p less than 0.01) respectively when the coagulase-negative staphylococci were not included. Adverse experiences occurred in 4.2% of the patients receiving norfloxacin compared to 7.1% of the placebo patients. None of the adverse experiences was serious.
Assuntos
Conjuntivite Bacteriana/tratamento farmacológico , Norfloxacino/uso terapêutico , Doença Aguda , Adulto , Contagem de Colônia Microbiana , Conjuntivite Bacteriana/microbiologia , Método Duplo-Cego , Feminino , Humanos , Masculino , Norfloxacino/administração & dosagem , Norfloxacino/efeitos adversos , Soluções Oftálmicas , Placebos , Resultado do TratamentoRESUMO
In a controlled, randomized trial of 133 patients with proven urinary tract infections (UTIs), significantly more pathogens were found to be susceptible to norfloxacin than to trimethoprim-sulfamethoxazole (TMP-SMZ) (p less than 0.01). Among patients with pathogens susceptible to both drugs, more of those treated with norfloxacin were cured or improved (p = 0.06). When at least one patient variable, i.e., prior history of therapy, was corrected for, this difference became significant (p = 0.03). Norfloxacin eradicated 11 of 13 infections due to Pseudomonas aeruginosa and 6 of 7 due to enterococci. Five patients treated with norfloxacin and two treated with TMP-SMZ had relapses within 6 weeks. Significantly fewer adverse experiences occurred in patients receiving norfloxacin (p less than 0.01).
Assuntos
Norfloxacino/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Adulto , Idoso , Resistência Microbiana a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Norfloxacino/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Infecções Urinárias/microbiologiaRESUMO
Este es un estudio abierto no comparativo para evaluar la eficacia y seguridad de la norfloxacina en el tratamiento de pacientes con infecciones del tracto urinario (ITU) causadas por bacilos gramnegativos o cocos grampositivos sensibles al medicamento. Veinte pacientes con ITU definida por cultivos urinarios de 10 o mas colonias / ml recibieron 400 mg de norfloxacina c/12 horas durante 7 o 10 dias de tratamiento. Los resultados obtenidos mostraron una curacion clinica y bacteriologica en el 100% de los casos y no hubo evidencia de efectos colaterales significativos. Se comprobo que la norfloxacina es una excelente alternativa para el manejo de las ITU